title: Decreased binding of [11C]NNC112 and [11C]SCH23390 in patients with chronic schizophrenia.
abstract: OBJECTIVE
  Abnormality of cognitive function in schizophrenia has been suggested to be related to dopamine D1 receptor. However, the results of previous positron emission tomography (PET) studies of dopamine D1 receptor in schizophrenia were not consistent.
  
  
  METHODS
  In this study, six patients with schizophrenia in severe residual phase with chronic antipsychotic treatment and twelve healthy age-matched controls participated. Two different radioligands, [11C]NNC112 and [11C]SCH23390, for dopamine D1 receptor were used on the same subjects. Binding of the ligands was measured by PET, and statistical analysis was performed using one-way analysis of covariate (ANCOVA) with age as covariate.
  
  
  RESULTS
  Good correlations between binding potential values (BP(ND)) and age were observed in all regions of interest (ROIs) with both ligands. ANCOVA with age as covariate of BP(ND) values of all ROIs revealed that the patient group showed significantly lower BP(ND) value compared with the control group in both ligands.
  
  
  CONCLUSIONS
  In patients with chronic schizophrenia in severe residual phase with chronic antipsychotic treatment, the binding potential values of both ligands were significantly lower in the striatum and cortical regions than those of healthy controls.
authors.affiliation: Molecular Neuroimaging Group, Molecular Imaging Center, National Institute of Radiological Sciences, Inage-ku, Chiba, Japan.
authors.forename: Jun
authors.initials: J
authors.lastname: Kosaka
authors.forename: Hidehiko
authors.initials: H
authors.lastname: Takahashi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ito
authors.forename: Akihiro
authors.initials: A
authors.lastname: Takano
authors.forename: Yota
authors.initials: Y
authors.lastname: Fujimura
authors.forename: Ryohei
authors.initials: R
authors.lastname: Matsumoto
authors.forename: Shoko
authors.initials: S
authors.lastname: Nozaki
authors.forename: Fumihiko
authors.initials: F
authors.lastname: Yasuno
authors.forename: Yoshiro
authors.initials: Y
authors.lastname: Okubo
authors.forename: Toshifumi
authors.initials: T
authors.lastname: Kishimoto
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Suhara
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000494:pharmacology; D001552:Benzazepines / Q000378:metabolism*; D001572:Benzofurans / Q000378:metabolism*; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D002540:Cerebral Cortex / Q000378:metabolism; D003071:Cognition / Q000187:drug effects; D003342:Corpus Striatum / Q000378:metabolism; D005260:Female; D006801:Humans; D008024:Ligands; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography; D017447:Receptors, Dopamine D1 / Q000187:drug effects / Q000378:metabolism*; D012559:Schizophrenia / Q000378:metabolism*
chemical_list: D014150:Antipsychotic Agents; D001552:Benzazepines; D001572:Benzofurans; D008024:Ligands; D017447:Receptors, Dopamine D1; C534628:SCH 23390; C077123:NNC 112